Avant Diagnostics, Inc. (AVDX) Advancing Development of OvaDx® through Ongoing Calibration Testing
Avant Diagnostics, Inc. has commenced calibration testing of OvaDx®, a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. In a recent news release, the company indicated that it expects to complete this calibration testing later this month, allowing it to move forward with validation testing while forming the basis of the pre-submission package that will be delivered to the U.S. Food and Drug Administration for review and comment prior to the commencement of the OvaDx® 510(k) trial. “The entire Avant team has been working tirelessly over the…